Compare · IMNM vs NVO
IMNM vs NVO
Side-by-side comparison of Immunome Inc. (IMNM) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IMNM and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $173.66B, about 84.6x IMNM ($2.05B).
- IMNM has been more active in the news (6 items in the past 4 weeks vs 4 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 16 for IMNM).
- Company
- Immunome Inc.
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $2.05B
- $173.66B
- 1M return
- -31.20%
- -
- 1Y return
- +4.84%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 6
- 4
- Recent ratings
- 16
- 25
Immunome Inc.
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest IMNM
- William Blair initiated coverage on Immunome
- Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Immunome Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities
- Stifel initiated coverage on Immunome with a new price target
- Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors
- Alliance Global Partners initiated coverage on Immunome with a new price target
- Chief Scientific Officer Higgins Jack exercised 18,000 shares at a strike of $1.35, sold $334,224 worth of shares (13,200 units at $25.32) as part of a pre-agreed trading plan and gifted 8,800 shares, decreasing direct ownership by 7% to 56,250 units (SEC Form 4)
- Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Immunome to Present at the H.C. Wainwright 28th Annual Global Investment Conference
- Director Barchas Isaac sold $2,198,910 worth of shares (83,464 units at $26.35) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 92,211 units (SEC Form 4)
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank